Clearside Biomedical Submits New Drug Application for XIPERE for the Treatment of Macular Edema Associated with Uveitis
pharmaceutical-investing Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update
pharmaceutical-investing Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA
pharmaceutical-investing Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion
